News & updates
Daily Peptide Brief
A recurring editorial module: one regulatory item, one clinical research item, one scientific or industry item. Every entry carries a status tag, and null results are reported alongside positive ones.
Daily dossier
2026
Daily Peptide Brief
Three research streams · one development each · primary sources cited
- RegulatoryStream I
Agency reiterates warning on compounded and counterfeit incretin products
A renewed safety communication addresses unapproved GLP-1 preparations sold online, citing dosing errors and unverified content. Compounded preparations remain outside premarket review.
Not an approved productSource · Regulatory communication — primary source - Clinical researchStream II
Phase 3 triple-agonist programme reports interim safety data
Interim tolerability findings are consistent with earlier phase 2 gastrointestinal signals. Efficacy endpoints remain blinded; no approval exists for this compound in any jurisdiction.
Investigational — phase 3Source · Registry entry and sponsor disclosure - Science & industryStream III
Oral peptide delivery platform reports improved bioavailability in early study
A first-in-human pharmacokinetic study describes higher absorption using an absorption-enhancer formulation. Pharmacokinetic improvement does not establish clinical benefit.
Phase 1 — pharmacokineticsSource · Peer-reviewed publication
Daily intelligenceSection
Research News
Body-composition endpoints move to the centre of weight-management trials
Several programmes now prespecify lean mass measurement, reflecting a methodological shift rather than a proven clinical advantage.
Source-backed summary · primary document linked on expansion
A peptide cardiovascular programme reports a null primary endpoint
Favourable biomarker changes did not translate into event reduction — a recurring pattern worth remembering when reading mechanism-led claims.
Source-backed summary · primary document linked on expansion
Section
FDA Watch
Import measures target vials marketed as research peptides
Enforcement activity focuses on products whose labelling positions them outside medicine regulation while being marketed for human effects.
Source-backed summary · primary document linked on expansion
Additional peptide bulk substances placed under safety review for compounding
Evaluations cite incomplete characterisation and immunogenicity uncertainty. Review status is not an approval and not a prohibition on all use.
Source-backed summary · primary document linked on expansion
Section
Industry Updates
Peptide manufacturing capacity expands as demand outpaces supply
Capacity investment shapes availability and, indirectly, the size of the unapproved market. Industry activity is not evidence of clinical value.
Source-backed summary · primary document linked on expansion
Cosmetic peptide claims draw advertising scrutiny
Regulators in several markets have challenged wording that implies therapeutic effects for topical peptide products.
Source-backed summary · primary document linked on expansion
Section
Peptides to Watch
Amylin analogues: watch the phase 3 designs, not the headlines
An area with genuine mechanistic interest and, so far, limited long-term human data. We track design quality as it develops.
Source-backed summary · primary document linked on expansion
Antimicrobial peptides return to serious clinical attention
Resistance pressure has revived a field with a long history of translational failure. Early-stage status should be read literally.
Source-backed summary · primary document linked on expansion
Editorial disclaimer
This site is educational and does not provide medical advice, dosing protocols, or treatment recommendations. Regulatory status and evidence strength differ sharply between compounds. A “research use only” label does not indicate that a product is appropriate for human use. Decisions about medicines belong with a qualified clinician.